{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"35","value":"9088"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"AUCinf was calculated as AUClast + (Clast\\*/kel), where AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was the rate constant for terminal phase.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"PK parameters of PF-06463922 were determined for a small subset of Phase 2 participants and Japan LIC. These participants received PF-06463922 100 mg orally QD and were combined into 1 reporting group for PK analysis. Japan LIC was not included in single-dose PK analysis, ie, they did not contribute to Day -7 data.","id":"OG000","title":"Phase 2 and Japan LIC PK Analysis Set"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. Here, 'Overall Number of Participants Analyzed' signifies participants analyzed for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7","title":"Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 (Phase 2)","type":"SECONDARY","unitOfMeasure":"ng*hour/mL"}